Author Archives: James Frederick, PA-C, MMSc

Positive Phase 1 Parkinson’s Trial Results of New Therapy Reported by Prothena

Prothena recently presented results from a Phase 1b clinical trial investigating a new antibody therapy for the treatment of Parkinson’s disease at the 13th​ International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Vienna, Austria. The trial was an ascending dose study of a novel antibody known as PRX002/RG7935.

3-D Images of Mutated Protein Variations May Increase Understanding of Parkinson’s

3-D images of 11 mutant versions of a protein connected with Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) are helping scientists understand how the mutations changed the structure of the protein and damaged its functioning. The study, “Structural insights into human angiogenin (ANG) variants implicated in Parkinson’s disease…